PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug development
Abstract Improved PET/CT radiopharmaceuticals can better visualize and monitor tuberculosis and enable real-time pharmacological drug profiling in vivo. PET/CT imaging can therefore be used to study in animal models the changes in tissue pathology in tuberculosis infection, such as mycobacterial lat...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | npj Imaging |
| Online Access: | https://doi.org/10.1038/s44303-025-00082-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850242871298359296 |
|---|---|
| author | Janke Kleynhans Christiaan A. Gouws Thomas Ebenhan |
| author_facet | Janke Kleynhans Christiaan A. Gouws Thomas Ebenhan |
| author_sort | Janke Kleynhans |
| collection | DOAJ |
| description | Abstract Improved PET/CT radiopharmaceuticals can better visualize and monitor tuberculosis and enable real-time pharmacological drug profiling in vivo. PET/CT imaging can therefore be used to study in animal models the changes in tissue pathology in tuberculosis infection, such as mycobacterial latency, tuberculoma formation, lung cavitation or calcification, and extrapulmonary disease. This Perspective aims to critically evaluate the current and future contribution and role of PET imaging in anti-tuberculosis drug development. |
| format | Article |
| id | doaj-art-27709e580a8247cfacdc38bbf2fc6c85 |
| institution | OA Journals |
| issn | 2948-197X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Imaging |
| spelling | doaj-art-27709e580a8247cfacdc38bbf2fc6c852025-08-20T02:00:09ZengNature Portfolionpj Imaging2948-197X2025-05-013111210.1038/s44303-025-00082-2PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug developmentJanke Kleynhans0Christiaan A. Gouws1Thomas Ebenhan2Department of Pharmaceutical and Pharmacological Sciences, Radiopharmaceutical Research, Katholieke Universiteit LeuvenPreclinical Imaging Facility, Nuclear Medicine Research Infrastructure NPCPreclinical Imaging Facility, Nuclear Medicine Research Infrastructure NPCAbstract Improved PET/CT radiopharmaceuticals can better visualize and monitor tuberculosis and enable real-time pharmacological drug profiling in vivo. PET/CT imaging can therefore be used to study in animal models the changes in tissue pathology in tuberculosis infection, such as mycobacterial latency, tuberculoma formation, lung cavitation or calcification, and extrapulmonary disease. This Perspective aims to critically evaluate the current and future contribution and role of PET imaging in anti-tuberculosis drug development.https://doi.org/10.1038/s44303-025-00082-2 |
| spellingShingle | Janke Kleynhans Christiaan A. Gouws Thomas Ebenhan PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug development npj Imaging |
| title | PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug development |
| title_full | PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug development |
| title_fullStr | PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug development |
| title_full_unstemmed | PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug development |
| title_short | PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug development |
| title_sort | pet imaging of mycobacterial infection transforming the pipeline for tuberculosis drug development |
| url | https://doi.org/10.1038/s44303-025-00082-2 |
| work_keys_str_mv | AT jankekleynhans petimagingofmycobacterialinfectiontransformingthepipelinefortuberculosisdrugdevelopment AT christiaanagouws petimagingofmycobacterialinfectiontransformingthepipelinefortuberculosisdrugdevelopment AT thomasebenhan petimagingofmycobacterialinfectiontransformingthepipelinefortuberculosisdrugdevelopment |